National Health Authority invites comments on drug registry consultation paper

The Drug Registry intends to create a nationally recognized source of truth for information on various systems of medicine in the country

0
63
New Delhi: The National Health Authority (NHA) has released a consultation paper on Drug Registry that is intended to be a single, up-to-date, centralized repository of all the drugs across all systems of medicine.
Envisioned under the ambitious Ayushman Bharat Digital Mission (ABDM), Drug Registry will be for the drugs that are approved and available in the Indian market.
The Drug Registry application is proposed be designed using open-source technologies and will be interoperable.
The consultation paper focuses only on Drug Registry within the National Digital Health Ecosystem and offers NHA’s current vision on the functionalities of the proposed Drug Registry, the process for its creation and potential benefits to various ecosystem stakeholders. Each section has specific open questions where feedback from stakeholders is sought. Comments from the public are invited to ensure that Drug Registry is designed and developed in a collaborative and consultative manner.
Dr. R. S. Sharma, CEO, National Health Authority, remarked, “Through Drug Registry, ABDM aims to provide a standardized, comprehensive set of verified data on all the approved drugs marketed in the country that would enable a more efficient regulatory process. To enable inclusivity and widen the perspectives on the table, I urge all stakeholders to go through the shared consultation papers and provide us with their valuable feedback.”
NHA will also organize a public webinar on Drug Registry to explain the consultation paper on 19th April’22 from 3 pm onwards. The link will be shared on the ABDM website https://abdm.gov.in/
Full text of the consultation paper is available for download on ABDM’s website at https://abdm.gov.in/home/Publications. Comments and feedback can be uploaded on the same link or can be emailed to [email protected] till 1st May’22.